Kazia Therapeutics Ltd Sponsored ADR (KZIA)
NASDAQ (CM) NASDAQ (CM) Primary 
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?
Kazia Therapeutics Limited KZIA stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with the FDA.
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Australian biotech company Kazia Therapeutics (NASDAQ: KZIA ) stock rocked the market after reporting encouraging results from a Phase II/III trial for its glioblastoma brain cancer therapy Paxalisib. The positive results extended the life of patients by over three months compared to the current standard of care.
Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics
Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers?
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.
KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains
Kazia Therapeutics (NASDAQ: KZIA ) stock is continuing to rally on Thursday after the company reported positive alongside clinical trial data yesterday. The Kazia Therapeutics clinical trial covered the company's paxalisib as a treatment of glioblastoma.
Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment
Kazia Therapeutics Limited KZIA released results on Wednesday from the GBM-AGILE Phase 2/3 study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma, a type of brain cancer.
Why Is Kazia Therapeutics (KZIA) Stock Up 300% Today?
Kazia Therapeutics (NASDAQ: KZIA ) stock is soaring higher on Wednesday after the oncology-focused biotechnology company provided results from a Phase II/III clinical trial. These results concern the effectiveness of paxalisib as a treatment of glioblastoma versus the standard of care (SOC).
